Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Takeda investigators describe new inhibitors of CDC7-related protein kinase

Sep. 28, 2010

AstraZeneca's phase III zibotentan trial in CRPC does not meet primary endpoint

Sep. 28, 2010

MRC Technology patents novel protein kinase inhibitors

Sep. 28, 2010

CHMP recommends approval of Tasigna in E.U. as first-line therapy for Ph+ CML

Sep. 28, 2010

PLX-4032 shows promise to treat BRAF mutation-positive melanoma

Sep. 28, 2010

NexMed and Bio-Quant present preclinical data on PrevOnco

Sep. 28, 2010

FDA orphan drug status for darinaparsin in peripheral T-cell lymphoma

Sep. 27, 2010

S*BIO obtains funding to support clinical programs

Sep. 27, 2010

FDA and EMA to review vandetanib for advanced medullary thyroid cancer

Sep. 27, 2010

Pro-Pharmaceuticals and Numoda collaborate on phase III Davanat trial

Sep. 27, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...